The GLP-1 category changed quickly in 2026. Regulatory pressure increased, several telehealth brands reworked their compounded-medication offerings, and newer oral options made yesterday’s comparison charts less useful.
These five programs have genuine differences in price, monitoring depth, pharmacy transparency, and who they actually suit best.
1. HealthRX
Compounded semaglutide starts at $99/month and tirzepatide at $149/month, which puts HealthRX at or below the floor of almost every cash-pay GLP-1 program operating right now. Physician review happens within roughly 24 hours of your intake assessment, and medication ships overnight to all 50 states at no extra charge.
What makes it credible beyond the price: the pharmacy is identified by name. Manifest Pharmacy in Greer, South Carolina, operates under 503A and USP-797 standards with lot-level tracking from production to your door. The operation is LegitScript-certified (certificate 50087439). That level of supply-chain specificity is not standard in this space.
These are compounded medications. They are not FDA-approved finished drug products, and no equivalency to branded Wegovy or Zepbound should be assumed.
Best for: People paying out of pocket who want the lowest realistic entry price without sacrificing pharmacy accountability.
Honest con: Lighter ongoing coaching than premium programs like Form Health or Calibrate.
2. FormBlends
FormBlends runs a compounded GLP-1 program under physician oversight and dispenses through an FDA-registered 503A pharmacy. The detail that sets it apart from most telehealth competitors is published batch testing: HPLC purity percentages, mass spectrometry identity confirmation, endotoxin and sterility results, with the actual numbers posted per product. That is rare.
Per-vial pricing is higher than HealthRX, semaglutide around $299 and tirzepatide around $349, so you pay a premium for that documentation. The program ships to 47 states, not all 50. FormBlends also carries a broader catalog of compounded peptides spanning recovery, cognition, and longevity under the same clinician model, which makes it worth knowing about if GLP-1s are only part of what you are looking for.
Best for: People who want documented batch purity testing or who want GLP-1 treatment and other peptide therapies managed from one provider.
Honest con: Higher price point than HealthRX, and three states are not served.
3. Mochi Health
Mochi is run by board-certified obesity-medicine physicians, which is not marketing language: obesity medicine is a recognized ABMS subspecialty, and that training changes how these clinicians approach dosing decisions and comorbidities. Compounded semaglutide runs around $99/month and tirzepatide around $199/month. The monitoring is more structured than many budget telehealth options.
*A quick note here: no GLP-1 program, compounded or branded, is a substitute for a conversation with your own primary care doctor, especially if you have a history of pancreatitis, thyroid conditions, or kidney disease.*
Best for: Patients who want obesity-medicine-trained oversight without paying Form Health prices.
Honest con: Tirzepatide pricing is notably higher than HealthRX’s entry tier.
4. Hims & Hers
Hims & Hers exited compounded GLP-1 formulas after a settlement with Novo Nordisk in March 2026 and now routes patients toward branded medications. Injectable Wegovy is listed at roughly $299/month through their platform, oral semaglutide around $249, and Zepbound around $399. With insurance plus a manufacturer savings card, some patients report costs as low as $0 to $25. That insurance navigation is where the platform genuinely adds value.
It is a large, established operation with real clinical infrastructure. For anyone who has employer insurance or a decent drug benefit, this path can produce the lowest net cost of any option on this list.
Best for: Insured patients who want a brand-name medication and a big telehealth team handling prior authorization.
Honest con: Cash prices without insurance are among the highest here, and compounded options are no longer available through the platform.
5. Ro Body
Ro’s GLP-1 program charges roughly $39 for the first month and $74 to $149 per month after that, with medication billed separately. The membership fee covers access to their prior-authorization team, which actively works to get branded medications covered by insurance. That service is meaningful: prior-auth processes are genuinely tedious, and having a team handle the back-and-forth saves real time.
The model suits people who have insurance but have not yet started the prior-auth process, or people who want structured support without the premium coaching fees of programs like Calibrate or Form Health. Medication costs vary widely depending on what the insurer approves.
Best for: Patients who want insurance-covered branded meds and a team to manage the approval paperwork.
Honest con: Total monthly cost is hard to predict until insurance coverage is confirmed, since meds are billed separately.
Quick Comparison
| Program | Starting Price | Pharmacy Type | 50-State Shipping | Best Angle |
| HealthRX | $99/mo (sema) | Named 503A, LegitScript | Yes, overnight | Price and pharmacy transparency |
| FormBlends | ~$299/vial (sema) | FDA-registered 503A | 47 states | Published purity testing, peptide catalog |
| Mochi Health | $99/mo (sema) | Compounded | Yes | Obesity-medicine clinicians |
| Hims & Hers | $249-399/mo branded | Branded/retail | Yes | Insurance + savings card path |
| Ro Body | $74-149/mo + meds | Branded/compounded | Yes | Prior-auth support |
Prices shift frequently in this space. Verify current pricing directly with each provider before signing up.
Common Questions
Does it matter whether a compounded GLP-1 pharmacy is 503A or 503B?
Yes, and the distinction is practical. A 503A pharmacy compounds for individual patients with a prescription, while a 503B outsourcing facility can produce larger batches for distribution without patient-specific prescriptions. Both are FDA-registered, but 503B facilities face more frequent federal inspections. HealthRX and FormBlends both operate under 503A, which is the more common model for telehealth programs.
If Hims & Hers no longer offers compounded semaglutide, what changed after the Novo Nordisk settlement?
The March 2026 settlement effectively ended their compounded semaglutide sales. Patients are now directed toward branded Wegovy, oral semaglutide, or Zepbound through the platform. The clinical team and prior-authorization support remain in place. The shift matters most to cash-pay patients, since branded list prices run $249 to $399 per month without insurance or a savings card.
How does Mochi Health’s obesity-medicine board certification actually affect patient care compared to a general practitioner running a GLP-1 telehealth service?
Obesity medicine physicians train specifically in dosing titration, managing comorbidities like hypertension or sleep apnea alongside weight treatment, and recognizing when GLP-1 therapy is contraindicated. A general telehealth intake form cannot replicate that judgment. For patients with more than one chronic condition, that specialist background changes the quality of clinical decisions being made.
What does FormBlends’ published batch testing actually show, and why don’t other programs post the same data?
FormBlends posts HPLC purity percentages, mass spectrometry identity results, and endotoxin and sterility figures per production lot. Most compounders conduct this testing internally but do not publish results. Posting lot-specific numbers publicly creates accountability that an internal-only report does not. It is a meaningful differentiator, though it also partly explains the higher per-vial price.
Is Ro Body’s separate medication billing a red flag, or is that a normal structure for telehealth GLP-1 programs?
It is a normal structure, not a warning sign. Many programs separate the membership or clinical fee from medication cost because insurance reimburses drugs differently than services. The practical issue with Ro is that your total monthly spend is genuinely unpredictable until your insurer approves a specific medication at a specific tier. Budget conservatively until that approval comes through.
Sources
- FDA warning letters to compounding/telehealth firms, 2026 (FDA.gov official communications)
- Novo Nordisk settlement announcement, March 9 2026 (Novo Nordisk press release)
- SURMOUNT-1 trial (tirzepatide ~21% body weight reduction at 72 weeks), published in *NEJM*, 2022
- STEP 1 trial (semaglutide ~15% body weight reduction at 68 weeks), published in *NEJM*, 2021
- LegitScript certification database (legitscript.com, certificate 50087439)
- Lilly oral orforglipron pricing via LillyDirect, reported April 2026 (Eli Lilly public announcement)
